Sinopharm Group CoSHTDF -2.67%78 Interest Coverage is 8.14 as of Dec. 2025, which is 43% above its 10-year median of 5.69. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 91 Medical Distribution companies, Sinopharm Group Co ranks better than 53.85% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Sinopharm Group Co's
Operating Income
for the
six
months ended in Dec. 2025 was $1,333 Mil. Sinopharm Group Co's Interest Expense for the
six
months ended in Dec. 2025 was $-164 Mil.
Sinopharm Group Co's interest coverage for the quarter that ended in Dec. 2025 was 8.14.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Sinopharm Group Co's Interest Coverage or its related term are showing as below:
SHTDF'
s Interest Coverage Range Over the Past 10 Years
Min: 4.45 Med: 5.69 Max: 7.53
Current: 7.43
SHTDF's Interest Coverage is ranked better than 53.85% of 91
companies
in the Medical Distribution industry
Industry Median: 6.92
vs SHTDF: 7.43
Sinopharm Group Co (OTCPK:SHTDF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Sinopharm Group Co Interest Coverage Related Terms
Sinopharm Group Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SHTDF vs MCK, COR, CAH: Interest Coverage Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Interest Coverage vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDF) has a Interest Coverage of 8.14 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sinopharm Group Co and its competitors. This is 43% above median its historical median of 5.69. Over the past decade, Sinopharm Group Co's Interest Coverage has ranged from 4.45 to 7.53. According to the industry distribution chart, Sinopharm Group Co ranks #42 out of 91 companies in the Medical Distribution industry, placing it in the top 46.2%.
Is Sinopharm Group Co's Interest Coverage too high?
Sinopharm Group Co's current Interest Coverage of 8.14 is 43% above median its 10-year median of 5.69. Over the past 10 years, this metric has ranged from a low of 4.45 to a high of 7.53. The Medical Distribution industry median Interest Coverage is 6.92. Sinopharm Group Co's value of 8.14 is 17.6% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #42 out of 91 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Interest Coverage compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #42 out of 91 companies for Interest Coverage. This puts Sinopharm Group Co in the upper half of its industry. The industry median Interest Coverage is 6.92. Sinopharm Group Co's value of 8.14 is 17.6% above this benchmark. Historically, Sinopharm Group Co's own Interest Coverage has ranged from 4.45 to 7.53 over the past decade. While the company's 10-year median is 5.69 vs. the industry median of 6.92, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Distribution company?
The median Interest Coverage among Medical Distribution companies is 6.92, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Interest Coverage of 8.14 is 17.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Interest Coverage is 6.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Interest Coverage is 8.14, which is 43% above median its own 10-year median of 5.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current Interest Coverage is 8.14, which is 43% above median its 10-year median of 5.69 and 17.6% above the Medical Distribution industry median of 6.92. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Interest Coverage is 8.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Interest Coverage: 8.14 (43% above median its 10-year median of 5.69)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 17.6% above the Medical Distribution median (#42 of 91)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
